Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1906215 | 1.00 | TP53 (0.67) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3155232 | 1.00 | TP53 (0.67) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL32688158 | 0.98 | TP53 (0.65) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL32688148 | 0.98 | TP53 (0.65) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL9850874 | 0.88 | TP53 (0.70) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL9821188 | 0.85 | TP53 (0.67) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL32688308 | 0.84 | TP53 (0.74) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL20573309 | 0.84 | TP53 (0.74) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL32688612 | 0.83 | TP53 (0.72) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL11553488 | 0.81 | LMNA (0.71) | TP53TSHRHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090582-A1 | COMPOSITIONS CONTAINING A NON-XANTHINE CNS STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250049805-A1 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC | 2025-02-13 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240316057-A1 | PULSATILE RELEASE CAFFEINE FORMULATION | GALVENTA AG (TR) | 2024-09-26 | — | — | US | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | claimed |
| US-20090291999-A1 | Agent Exhibiting a Neurotropic, Neuromodulator, Cerebrovascular and Anti-Stroke Activity | AKHAPKINA, VALENTINA IVANOVNA (RU) | 2009-11-26 | — | — | US | claimed |
| WO-2009105853-A2 | PHARMACEUTICAL COMPOSITION | BIOLAB SANUS FARMACEUTICA LTDA. (BR) | 2009-09-03 | — | — | WO | claimed |
| US-20090176740-A1 | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine | PHILLIPS II DAUGLAS JAMES | 2009-07-09 | — | — | US | claimed |
| CN-101415418-A | Pharmaceutical preparation exhibiting neurotropic, neuromodulator, cerebrovascular and anti-stroke activity | IVANOVNA AKHAPKINA VALENTINA (RU) | 2009-04-22 | — | — | CN | claimed |
| EP-2011497-A1 | AGENT EXHIBITING A NEUROTROPIC, NEUROMODULATOR, CEREBROVASCULAR AND ANTI- STROKE ACTIVITY | Akhapkina, Valentina Ivanova (RU) | 2009-01-07 | — | — | EP | claimed |
| WO-2007104781-A2 | METHOD FOR MANUFACTURING OF R-ENANTIOMER OF N-CARBAMOYLMETHYL-4-PHENYL-2-PYRROLIDONE | AKCIJU SABIEDRIBA 'OLAINFARM' (LV) | 2007-09-20 | — | — | WO | claimed |
| US-20060287383-A1 | Substance exhibiting antidepressant property | AKHAPKINA VALENTINA I | 2006-12-21 | — | — | US | claimed |
| EP-1619182-A1 | SUBSTANCE EXHIBITING ANTIDEPRESSANT PROPERTY | Akhapkina, Valentina Ivanova (RU) | 2006-01-25 | — | — | EP | claimed |
| EP-1203585-B1 | ANTI-ISCHEMIC AGENT | ZAKRYTOE AKTSIONERNOE OBSCHEST (RU) | 2005-03-16 | — | — | EP | claimed |
| EP-1203585-A1 | ANTI-ISCHEMIC AGENT | Zakrytoe Aktsionernoe Obschestvo "ASGL-Issledovatelskie Laboratorii" (RU) | 2002-05-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049805-A1 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | CPT1B, PYGB, HADHB | TP53 4677/4885TSHR 3239/4885HPGD 396/4885 |
| US-20240316057-A1 | PULSATILE RELEASE CAFFEINE FORMULATION | CRH, HCRTR1, HTR1A | TP53 4883/4885TSHR 361/4885HPGD 1153/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | TP53 4516/4885TSHR 958/4885HPGD 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.